Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fv-LDP-D3
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Medical Sciences and Peking Union Medical College
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Fv-LDP-D3 is a recombinant fusion protein designed for targeted cancer therapy, particularly for EGFR-overexpressing tumors such as esophageal and colorectal cancer. It is composed of the single-chain variable fragment (Fv) of an anti-EGFR antibody, the apoprotein of lidamycin (LDP), and domain III of human serum albumin (D3). Fv-LDP-D3 binds specifically to EGFR, is internalized via macropinocytosis, inhibits EGFR phosphorylation, downregulates inosine monophosphate dehydrogenase type II (IMPDH2), suppresses cell proliferation, and induces apoptosis in tumor cells. The addition of the D3 domain intensifies tumor uptake and tumor retention. It has demonstrated preclinical efficacy in animal models against esophageal and colorectal cancer, functioning as a tumor-targeted delivery platform[1][4][7][8].
- Brand names
- Fv-LDP-D3Fv-LDP-D-3Fv-LDP-D 3
- Other names
- Fv-LDP-D3Fv-LDP-D-3Fv-LDP-D 3
02
Targets
EGFR (Epidermal growth factor receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on Fv-LDP-D3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fv-LDP-D3.